Promoter holding
64.27%
IB
Indus Biotech Limited - Due diligence report
A 360° intelligence report on Indusbiotech: trust score, financial health, credit view, compliance, directors, growth and distress signals -…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Indusbiotech — 360° Intelligence Report
Generated from MCA filings & public records72/100
Trust Score
Moderate
Indusbiotech is assessed as Moderate with a Trust Score of 72/100. Indusbiotech is an active public limited indian non-government company incorporated in 1995, operating in the Life Sciences sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.
Report generated on 18 Oct 2026 from the latest processed filings. Indus Biotech Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
72/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
50/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
70/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
85/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
45/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 85/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 2 open (2.93 cr) · 8 satisfied (22.02 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 2 | 48.0 cr |
| Vijaya Bank | 7 | 48.0 cr |
| Vijaya Bank Limited | 1 | 48.0 cr |
Compliance Score: 50/100 Moderate
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2025).
- Litigation present in 4 court forum(s).
- 1 auditor resignation(s) filed - latest: Price Waterhouse & Co. Bangalore LLP on 2018-07-16.
- Delayed payments to MSME suppliers disclosed (384 disclosure(s)).
- 1 active GST registration(s).
Legal cases on record (4)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| RAJAN RAMASWAMY SRINIVASAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ACHYUT JAYATIRTHRAO HUILGOL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ACHYUT JAYATIRTHRAO HUILGOL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RANJEET PALLIYIL SRINIVASAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHRIKANT JAYAWANT PATIL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANIL PRATAP KUMAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PANKAJ MEHRA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Rucha Shamkant Khaire | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SUNIL DUTT BHASKARAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 9 directors on the board.
- No disqualified or deactivated DINs.
- 2 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
1
Group entities
1
Capital events
1 allotment(s) · 5 transfer(s)
Promoters hold the largest single block of equity - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Trigonella Labs Private Limited | Subsidiary Company | 74.00% |
Key managerial personnel: ACHYUT JAYATIRTHRAO HUILGOL (CFO) · ACHYUT JAYATIRTHRAO HUILGOL (CFO) · SUNIL DUTT BHASKARAN (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 45 · Distress 75
Growth signals & trust indicators
EPFO headcount growing - hiring signal.
Operating for 31+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Compliance score is weak (50/100).
2 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 88.28 Lakh.
4 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence64/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment72/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 2 open charge(s) of 2.93 cr already registered.
- Compliance gaps should be priced into terms.
Investor view60/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 1 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2025
Last AGM held
Annual general meeting
29 Sep 2025
Director ceased
PANKAJ MEHRA
26 Sep 2025
Director appointed
PANKAJ MEHRA (Director)
30 Jun 2025
Director ceased
HIMANSHU NIVSARKAR
31 Mar 2025
Latest balance sheet
Filed with ROC
30 Aug 2023
Director ceased
JAIPRAKASH PRABHAKARAN MUDAKKANAVEETIL
18 Jul 2023
Director ceased
RAJESHREE RAJNIKANT SABNAVIS
15 Nov 2021
Director appointed
SHRIKANT JAYAWANT PATIL (Director)
Director appointed
ANIL PRATAP KUMAR (Director)
21 Sep 2021
Director ceased
NITIN JAGANNATH DESHMUKH
14 Sep 2021
Securities allotted
1535474 Equity Shares - 78.94 cr raised
23 Jun 2021
Charge created
Others - 2.00 cr
31 Dec 2020
Director ceased
SUNIL DUTT BHASKARAN
06 Jul 2020
Charge satisfied
Others
31 Mar 2020
Share transfer (FY 2020)
78755.00000000 shares to Mehra Durgadas Chetan
10
Key Observations
Auto-generated from the data aboveRevenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Net worth is positive.
9 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold the largest single block of equity as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
4 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| THRIVING ALPHA INVESTMENT ADVISORS LLP | AAX-1265 | Pune, Maharashtra |
| Leo Mineral Private Limited | U13206PN2022PTC213307 | Pune, Maharashtra |
| Armada Financial Services India Private Limited | U70200PN2024PTC235446 | Pune, Maharashtra |
| Tradefit Petro Impex Private Limited | U19201PN2025PTC237909 | Pune, Maharashtra |
| Adyan Traders Private Limited | U46301PN2024PTC228045 | Pune, Maharashtra |
| Tribuzz Technologies Private Limited | U74999PN2022PTC208656 | Pune, Maharashtra |
| Unity Craft Mobilier Private Limited | U36999PN2019PTC183700 | Pune, Maharashtra |
| Endeavour Aircon Private Limited | U26109PN2023PTC220242 | Pune, Maharashtra |
| Intelliserve Analytics & Solutions Private Limited | U63999PN2023PTC221417 | Pune, Maharashtra |
| Alfafit Zone Private Limited | U74999PN2022PTC211830 | Pune, Maharashtra |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Indusbiotech before audits and certifications: compliance score 50/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Indusbiotech: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 85/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 45/100, margin trends, ownership structure and peer set for Indusbiotech - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 72/100, distress signals and MSME payment-delay disclosures - know whether Indusbiotech pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (4 case(s) on record), regulatory flags, charge documents trail and director networks for Indusbiotech - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Indusbiotech an active company?
Indusbiotech has MCA status “Active” with a compliance score of 50/100 (Moderate).
Is Indusbiotech financially healthy?
Indusbiotech has a Financial Health Score of 70/100 (Moderate) based on its filed financial statements.
Should I do business with Indusbiotech?
Its overall Trust Score is 72/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Indusbiotech?
Promoters hold the largest single block of equity - exact percentages are in the full report. 9 active director(s) are on record.
Does Indusbiotech have loans or charges against its assets?
2 open charge(s) are registered against its assets, and 8 earlier charge(s) stand satisfied.
Is Indusbiotech up to date with its ROC filings?
Balance sheet slightly behind (Mar 2025). Overall compliance score: 50/100 (Moderate).
Is it risky to lend to Indusbiotech?
Its Credit Risk Score is 85/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
